A pivotal policy document released by the National Healthcare Security Administration in August set the stage for a fundamental shift in China's medical insurance landscape.
For the first time, the national plan clearly delineates the functional boundaries between basic medical insurance and commercial health insurance, elevating the latter from a mere supplementary option to an indispensable pillar of the country's healthcare security system.
For an industry that has long operated within the residual spaces of basic medical insurance reimbursement, this represents a long-overdue yet crucial redefinition of its role. Over the past decade, commercial health insurance premiums have surged from billions to nearly one trillion yuan by 2025, with an average annual growth rate exceeding 20%. However, this expansion in scale has not translated into comparable depth of coverage: in 2025, the insurance density stood at approximately 0.72%, while payments for innovative drugs accounted for only about 7.8% of the market. While the money flowing into the system has increased, the proportion directed towards innovative pharmaceuticals and areas not covered by basic insurance remains disproportionately low—a structural issue the new plan seeks to rectify.
Clarifying Basic Insurance Boundaries to Unlock Commercial Potential
The starting point of the plan is to clearly define the scope of basic medical insurance. It maintains that the participation rate for basic insurance will remain around 95% during the 2025-2030 period, with reimbursement rates for inpatient expenses within the basic drug catalog stabilizing at about 80% for employee insurance and 70% for urban and rural resident insurance. This underscores that basic insurance's role as the foundation of broad coverage will not change; it remains the anchor of the entire healthcare system.
Precisely because the function of basic insurance is clearly limited to providing fundamental protection, commercial insurance gains greater room to expand. The plan explicitly supports and guides the complementary, differentiated development of commercial medical insurance alongside basic coverage, focusing on products that cover expenses beyond the basic insurance catalog, offer high affordability, and support innovation in medicine. This directive serves as a remedy for years of homogeneous, low-level competition within the industry. Many existing health insurance products largely duplicate the coverage of basic insurance, leading to minimal differentiation, poor claims experiences, and narrow applicability. The plan aims to use policy leverage to push the industry away from repetitive competition and towards developing unique, high-value coverage options, such as out-of-hospital specialty drugs, innovative therapies, advanced medical devices, and cutting-edge diagnostic solutions.
In terms of functional evolution, commercial health insurance is undergoing a four-fold transformation: from a mere supplement to basic insurance, to an accelerator for innovative drugs and devices, to a collaborator within the multi-tiered insurance system, and ultimately, to a provider of comprehensive health management services rather than just post-hoc claims payouts.
Pioneering a Dual-Track Payment System for Innovative Drugs
Perhaps the most groundbreaking aspect of the plan is the restructuring of payment mechanisms for innovative drugs. In December 2025, the first commercial insurance innovative drug catalog was released, including 19 drugs that cover therapies like CAR-T cell treatment and medications for rare diseases, some of which cost over one million yuan. These drugs share high clinical value and innovation but are at a disadvantage in standard medical insurance negotiations due to their high prices and limited patient populations, constrained by the financial limits of the basic insurance fund. The new commercial catalog offers an independent payment channel, meaning these therapies are no longer solely dependent on access through the basic insurance system.
A notable development is the establishment of a "dual-catalog" linkage mechanism, allowing drugs listed in the commercial insurance catalog to also apply for inclusion in the national basic medical insurance catalog. The results of the preliminary review for the 2026 adjustment, announced in late June, show that 54 drugs passed the initial review for the commercial catalog, with an overall pass rate of 92%, and 44 drugs applied for both catalogs simultaneously. This indicates that the commercial catalog is no longer an isolated list but is now dynamically interconnected with the national catalog. The plan provides explicit policy backing for this, stating it will support the inclusion of qualified innovative drugs in the medical insurance catalog and improve the commercial insurance innovative drug list. It also encourages, on a risk-controllable and sustainable basis, the inclusion of new medical technologies, services, drugs, and devices in commercial insurance coverage. This shifts the payment logic for innovative drugs from a binary choice of "either covered by insurance or paid out-of-pocket" to a three-tier system of "medical insurance, commercial insurance special catalog, and self-pay."
By the end of May 2026, over 100 city-level supplemental insurance products (known as "Huiminbao") across the country had expanded their coverage to include drugs from the commercial innovative drug catalog. For ordinary patients, this means that even if an innovative drug is not yet covered by basic insurance, they may still receive substantial financial support through commercial insurance, avoiding the burden of fully self-funding treatments that can cost millions.
However, a significant gap remains between the current 7.8% penetration rate for innovative drug payments and the large premium base. The pace of establishing the institutional framework has outpaced actual market adoption, reflecting constraints in product design, pricing capabilities, and consumer awareness. The key test for insurance companies in the coming years will be their ability to integrate innovative drug coverage into mainstream products, rather than keeping it as a marginal feature in a few supplemental plans.
Data Sharing and Real-Time Settlement: Unlocking Long-Awaited Infrastructure Dividends
While the catalog linkage addresses what is covered, data sharing and synchronized settlement address how coverage is used, tackling a core pain point that has long hindered consumer adoption of commercial health insurance. The plan explicitly calls for promoting data sharing and synchronized settlement between basic medical insurance and commercial insurance, supporting fast claims and direct payment. Historically, the claims experience for commercial health insurance has been poor: patients had to pay all medical costs upfront, then collect receipts, invoices, and medical records to file a claim with the insurer, a process that was both cumbersome and time-consuming, deterring many potential buyers.
This situation is beginning to change. In the first half of 2026, Shandong Province launched a blockchain-based "medical insurance + commercial insurance" synchronized settlement model, creating a complete loop from policy purchase and claims to settlement. In Sichuan Province, the first one-stop settlement service was launched in Meishan, where patients with "Dongpo Huiminbao" have their commercial insurance payouts calculated automatically upon discharge. These pilots demonstrate that the old model of "pay first, reimburse later" is being replaced by "one-stop settlement at discharge."
Market-driven efforts are also advancing direct payment services. A major digital health platform announced in August its acquisition of a health services company to enhance its one-stop direct payment experience, with a network extending to over 1,500 private and public hospital international departments. This marks a shift from post-hoc reimbursement to real-time settlement, where the financial transaction occurs seamlessly in the background during a medical visit.
The rollout of this infrastructure could bring dual benefits. For consumers, a significantly reduced claims threshold would directly increase their willingness to purchase commercial health insurance. For insurers, access to comprehensive diagnostic and treatment data through linkage with the medical insurance system would be crucial for optimizing actuarial models and improving anti-fraud and risk control capabilities, mitigating issues like adverse selection and runaway medical costs. Nevertheless, the phrase "in accordance with the law" sets clear boundaries. Data security and privacy protection are non-negotiable red lines, meaning the specific scope of data sharing, usage limits, and technical standards will require detailed implementation rules. The current practices in Shandong, Sichuan, and Qingdao are essentially local pilots; a unified national technical standard and settlement protocol is still forthcoming, and bridging the differences between the two systems involves not just technical interfaces but also reconciling two distinct governance logics, a process not to be underestimated.
Long-Term Care Insurance: A New Growth Frontier in an Aging Society
Beyond innovative drug payments and settlement experiences, the plan also focuses on the nationwide rollout of the long-term care insurance system. It sets a target for the system to cover all coordinated regions during the 2025-2030 period, achieving full coverage by 2030, while also calling for improved care services and technical capabilities in this field. This policy direction is a response to China's rapidly aging population. While the basic long-term care insurance system will achieve geographic coverage, its role is still defined as providing basic protection, with limitations in care level assessments and service options. This limitation creates a clear growth opportunity for commercial health insurance to address the diverse and personalized needs of disabled elderly and those with chronic conditions. Commercial long-term care and disability insurance are expected to become key areas of product innovation, focusing on home care, professional nursing institutions, and smart care equipment.
The plan's mentions of improving outpatient care for chronic and special diseases and enhancing maternity protection also open up ancillary market possibilities. The target customer base for commercial health insurance is expanding to include employees, workers in new employment forms, the elderly, and those with chronic conditions. However, long-term care insurance demands significantly higher professional expertise from insurers than traditional medical insurance. Actuarial models for long-term disability assessment and payouts are still underdeveloped in China compared to developed countries. To effectively capture this demand, insurers will need to go beyond selling policies and build or integrate care service networks and assessment systems, posing considerable challenges in terms of business model complexity and capital investment.
The plan charts a clear path for commercial health insurance: basic insurance will continue to provide a solid foundation, while commercial insurance is positioned to take on differentiated, multi-layered protection needs, particularly in areas like innovative drugs and long-term care that are constrained by the funding limits of basic insurance. The transition from "supplement" to "collaborator," from "pay first, reimburse later" to "one-stop settlement," and from "post-hoc claims" to "comprehensive health management" signifies a fundamental shift in its role. For insurance companies, the future advantage will lie not in scale or price wars but in capabilities in medical research, pharmaceutical negotiation, and health service integration. For ordinary consumers, the concept of a two-tier protection structure, with basic insurance as a foundation and commercial health insurance as an effective complement, is gradually becoming a tangible reality. The ultimate success of this plan will depend on the speed at which local pilots are scaled up nationwide and the industry's ability to deliver on its promises in the key areas of innovative drug payments, data collaboration, and long-term care.